Unknown Analyst

Hi, everyone. My name is [ Matthew Guggenbiller ]. I'm an associate on Alex Stranahan's biotech team.

Thanks for coming to the Vegas Conference, day 3. I appreciate you guys coming out, and I'm pleased to be joined by Aclaris Therapeutics, who are going to be running through some slides. Over to you.

Hugh M. Davis
President, COO & Director

Yes. Hi. Good morning. I'm Hugh Davis. I'm the President and COO for Aclaris Therapeutics, and thanks to Bank of America for having us at their health care conference.

The normal disclaimer and cautionary notes regarding forward-looking statements. Aclaris Therapeutics is an innovator in immunological assets for important unaddressable disease. And addressing validated targets is key to success while we are really understanding how to take innovative approaches to our portfolio.

And 2 examples would be bispecifics and ITK oral inhibitors that will be best-in-class. We have a research lab in St. Louis that is state-of-the-art scientific platform in kinase biology and world-class scientific acumen across the company.

In 2026, we have a quite catalyst calendar that I'll speak to later. As I mentioned, addressable I&I diseases of dermatologic, immunologic in terms of respiratory and IBD disease is important with an impact in millions of patients just in the U.S. alone.

And so in Aclaris, we are going after these respiratory and dermatologic conditions with first-in-class types of molecules. It's unusual for a SMID-Cap to have such a strength in large and small molecule development and therapeutics.

And yet we have both ITK franchise that has JAK-like efficacy that we're looking to expand on with broad ITK